Cablivi

Product Overview

About Cablivi

Cablivi is a medicinal product.

What it is used for

Cablivi is used to treat patients with aTTP.

How it is used

Cablivi can only be obtained with a prescription. Treatment should be started and supervised by doctors experienced in managing patients who have clotting disorders affecting small blood vessels. Cablivi is started with a dose of 10 mg given by injection into a vein before plasma exchange. Treatment is continued with 10 mg daily given by injection under the skin in the belly after daily plasma exchange and continued for 30 days after daily plasma exchange is stopped. Treatment with Cablivi may continue for longer if necessary. Patients also receive treatments to reduce the immune system’s activity. Patients or their carers may be able to inject Cablivi themselves after appropriate training.

How it works

In patients with aTTP, levels of a substance called von Willebrand factor are increased. Von Willebrand factor acts on platelets to cause them to stick together and form blood clots. Caplacizumab, the active substance in Cablivi, is a nanobody (a small antibody) which has been designed to attach to von Willebrand factor in a way that stops it acting on platelets. This reduces platelets sticking together and forming clots in blood vessels and, as a result, platelet levels in the blood rise because they are no longer taken up to form clots.

Active substance: Caplacizumab

Source: EMA EPAR